Currently, the only reported study on POGK gene indicates its upregulation in hepatocellular carcinoma patients and correlates with poor prognosis and immune cell abundance in the tumor microenvironment, suggesting it as an effective therapeutic target for this patient population. This evidence concerns the gene POGK and neoplasm.